RC-402 is under clinical development by Virocure and currently in Phase I for Gastrointestinal Stromal Tumor (GIST). According to GlobalData, Phase I drugs for Gastrointestinal Stromal Tumor (GIST) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RC-402’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RC-402 is under development for the treatment of advanced malignant solid tumors including melanoma, gastric adenocarcinoma, gastro oesophageal junction adenocarcinoma, gastrointestinal stromal tumors, colon cancer and lung cancer. It is an oncolytic virus-based therapy. It is administered through intratumor route.
Virocure is a Pharmaceuticals and Healthcare company that provides treatment for Cancer. The company is Headquartered in Gurodong, Seoul, Republic of Korea (South Korea).
For a complete picture of RC-402’s drug-specific PTSR and LoA scores, buy the report here.